Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Nivolumab With Chemotherapy in Refractory MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- Status
- COMPLETED
- Phase
- PHASE3
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- Status
- UNKNOWN
- Phase
- PHASE4
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
- Status
- COMPLETED
- Phase
- PHASE1
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
- Status
- TERMINATED
- Phase
- PHASE1